SSY GROUP (02005): Low-calcium Peritoneal Dialysis Solution (Bicarbonate G1.5%) and Other Drugs Obtain Drug Production Registration Approval
SSY GROUP (02005) announced that the group has obtained drug production registration approvals from China's National Medical Products Administration (NMPA) for Low-calcium Peritoneal Dialysis Solution (Bicarbonate G1.5%), Peritoneal Dialysis Solution (Bicarbonate-G2.5%), Peritoneal Dialysis Solution (Bicarbonate-G4.25%), and Low-calcium Peritoneal Dialysis Solution (Bicarbonate-G4.25%) (the Products). All are in 2000ml specifications, belong to Class 3 chemical drugs, and are deemed to have passed consistency evaluation, among which Low-calcium Peritoneal Dialysis Solution (Bicarbonate-G4.25%) is the third approved by a domestic enterprise. The Products are mainly used for peritoneal dialysis in patients with chronic renal failure, and are used when hypermagnesemia has not been adequately improved.
SSY GROUP (02005) announced that the Group has obtained drug production registration approvals from China's National Medical Products Administration (NMPA) for Low-calcium Peritoneal Dialysis Solution (Bicarbonate G1.5%), Peritoneal Dialysis Solution (Bicarbonate-G2.5%), Peritoneal Dialysis Solution (Bicarbonate-G4.25%), and Low-calcium Peritoneal Dialysis Solution (Bicarbonate-G4.25%) (the "Products"). All are in 2000ml specifications, belong to Class 3 chemical drugs, and are deemed to have passed consistency evaluation, among which Low-calcium Peritoneal Dialysis Solution (Bicarbonate-G4.25%) is the third approved by a domestic enterprise. The Products are mainly used for peritoneal dialysis in patients with chronic renal failure, and are used when hypermagnesemia has not been adequately improved.
The Group continues its strategic deployment in the renal replacement therapy field, with products covering peritoneal dialysis solutions, hemofiltration replacement fluids, and others. The four approved peritoneal dialysis solutions are all dual-chamber bag formulations with a bicarbonate buffer system, employing a design of separate component storage and mixing prior to use, involving high process difficulty and technical barriers. The Products, combined with 1.5%/2.5%/4.25% glucose concentrations and standard-calcium and low-calcium formulations, can meet the clinical needs of patients with different conditions and combined calcium and magnesium abnormalities. The Products are emerging upgraded varieties in the peritoneal dialysis field, with a limited number of approved domestic enterprises and a favorable competitive landscape. Compared with traditional lactate-based formulations, they offer differentiated pricing space, and as clinical awareness increases, there is broad market penetration potential.
Following this approval, the Group has formed a domestically leading, comprehensively laid-out peritoneal dialysis solution product matrix, covering multiple technical routes including lactate and bicarbonate as well as multiple specifications, and relying on its mature large-volume infusion platform to achieve stable production and controllable quality. Peritoneal dialysis, as an important treatment modality for end-stage renal disease, offers the convenience of home operation and flexible scheduling, can complement and be used sequentially with hemodialysis, prolongs patient survival, and has rigid and sufficient clinical demand. Compared with hemodialysis, the domestic peritoneal dialysis market has significant room for penetration improvement and broad growth prospects. This approval will further improve the Group's nephrology dialysis pipeline and strengthen the competitiveness of its renal replacement therapy segment.
The Board is also pleased to announce that the Group has obtained drug production registration approval from the NMPA for Arginine Hydrochloride Injection (200ml:20g), which is the second approved by a domestic enterprise, belongs to Class 3 chemical drugs, and is deemed to have passed consistency evaluation. It is mainly used for emergency reduction of blood ammonia concentration when oral formulations cannot control acute exacerbation of hyperammonemia in certain diseases.
The Group continues to build its critical care treatment pipeline. The approved Arginine Hydrochloride Injection (200ml:20g) is a therapeutic large-volume infusion. Compared with the currently widely used small-volume ampoule formulations, this product requires no clinical dilution and preparation, facilitating use in critical emergency scenarios. This approval further enriches the Group's therapeutic infusion product line.
Related Articles

SA SA INT'L (00178) will pay an interim dividend of HK$0.04 per share on December 18.

SA SA INT'L (00178) announces interim results, profit attributable to shareholders HK$170 million, up 239.14% year-on-year; sales performance in core markets Hong Kong and Macau improved significantly.

CHONGQING M&E (02722) will pay an interim dividend of RMB0.02 per share on December 21.
SA SA INT'L (00178) will pay an interim dividend of HK$0.04 per share on December 18.

SA SA INT'L (00178) announces interim results, profit attributable to shareholders HK$170 million, up 239.14% year-on-year; sales performance in core markets Hong Kong and Macau improved significantly.

CHONGQING M&E (02722) will pay an interim dividend of RMB0.02 per share on December 21.






